Myeloid neoplasm

This trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protei…

This trial is for adults with relapsed or refractory acute myeloid leukemia (AML) who have no standard curative options. Researchers are testing whether giving the drug gemtuzumab ozogamicin followed by an infusion of donor white blood cells can stimulate the immune system to att…

This phase 2 trial tests a two-step approach to stem cell transplantation for people with blood cancers. The method separates the infusion of donor lymphocytes from stem cells, aiming to better control the dose and reduce the risk of graft-versus-host disease, a serious complicat…

This phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…

This study tests a personalized vaccine made from a patient's own leukemia cells fused with immune cells, combined with a drug that blocks PD-1, to help the immune system recognize and destroy any remaining leukemia cells after chemotherapy. The goal is to prevent the cancer from…

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

This phase 1 trial is testing whether a diet that severely limits arginine—an amino acid some tumors depend on—is safe and might help control solid tumors. About 25 adults with solid tumors will follow a specially designed low-arginine liquid diet for two 3-week cycles while cont…

This study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blo…

This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…

This early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for…

This study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…

This trial tests whether adding venetoclax to a standard chemotherapy pair (cytarabine and mitoxantrone) can help adults with acute myeloid leukemia that has relapsed or not responded to initial treatment. In the first phase, researchers find the highest safe dose of cytarabine w…

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This phase 2 trial tests a combination of four drugs, selinexor, bortezomib, lenalidomide, and dexamethasone (SVRd), in people newly diagnosed with multiple myeloma whose disease has spread outside the bone marrow, called extramedullary disease. The study aims to see how well thi…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…

This early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…

This early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer grow…

This trial is testing whether a new form of chemotherapy called PLX038 can be safely combined with the PARP inhibitor rucaparib to shrink tumors in people with small cell lung cancer, small cell cancer outside the lungs, or other solid tumors. The study has two parts: first, find…

This early-phase trial tests whether specially trained immune cells from a donor can safely target and kill cancer cells in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after a stem cell transplant. The cells are grown in a lab to recognize four prot…

This trial tests whether a combination of venetoclax (a targeted pill) plus a hypomethylating agent (azacitidine or decitabine) can help adults with newly diagnosed acute myeloid leukemia who are not eligible for intensive chemotherapy. The study includes older patients, those wi…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This phase 2 study tested a sequence of four drugs—carfilzomib, clarithromycin, lenalidomide, and dexamethasone—in 74 people newly diagnosed with multiple myeloma. The goal was to see how safe and effective this combination is at controlling the disease. Participants first receiv…

This phase 2 trial is testing whether adding venetoclax, a pill taken daily for 12 months, can reduce the number of leukemia stem cells that remain in the bone marrow of people with chronic myeloid leukemia (CML) who are already in deep molecular remission on standard TKI therapy…

This trial compares two oral medications for adults with chronic myeloid leukemia (CML) in its chronic phase who have already been treated with at least two other targeted therapies. Participants receive either the experimental drug asciminib or the existing drug bosutinib. The g…

This phase III trial is testing whether taking oral azacitidine as a maintenance therapy after an allogeneic stem cell transplant can help prevent relapse in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Participants are randomly assigned to receive…

This phase 1 trial is testing an investigational drug called AEB1102 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or stopped responding to standard treatments. AEB1102 is a modified human enzyme that breaks down arginine, an amin…

This study looked at whether people with chronic myeloid leukemia (CML) who have done very well on the drug nilotinib can safely stop taking it. 215 patients who had been on nilotinib for at least two years and had very low levels of cancer cells were enrolled. The main goal was …

This trial is testing whether a chemotherapy drug called treosulfan, given in different doses along with fludarabine, can safely prepare patients with advanced blood cancers for a stem cell transplant. The study focuses on patients who are not eligible for the standard, more inte…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This study looked at whether people with chronic myeloid leukemia (CML) who had very low levels of cancer cells could safely stop taking the drug nilotinib (Tasigna). Participants had already been treated with imatinib (Gleevec) and then nilotinib for at least 3 years. The main g…

This early-stage trial tests a combination of two drugs, venetoclax and azacitidine, in people with a serious type of myelodysplastic syndromes (MDS) who have not had treatment before. The goal is to find the safest dose and see how well the drugs work together to control the dis…

This trial is testing an experimental drug called BST-236 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not improved after initial treatment. Participants receive BST-236 as a one-hour intravenous infusion for six …

This phase III trial is testing whether adding selinexor to a standard two-drug regimen (bortezomib and dexamethasone) can help people with relapsed or refractory multiple myeloma—a blood cancer that has returned or stopped responding to treatment. About 154 adults with measurabl…

This early-phase trial tests a new type of immunotherapy for people who develop a rare blood cancer called post-transplant lymphoproliferative disease (PTLD) after a solid organ transplant. The treatment uses the patient's own immune cells (T-cells) that are engineered to resist …

This trial tests whether stem cells grown in the lab before being returned to the body can help blood counts recover faster after a stem cell transplant for multiple myeloma. Adults aged 18 to 65 with myeloma in first response will receive their own amplified stem cells. The main…

This phase II trial investigates whether eltrombopag, a drug that stimulates platelet production, can help older adults with acute myeloid leukemia (AML) recover their platelet counts faster after initial chemotherapy. Older patients often experience slow platelet recovery, which…

This phase 2 trial is testing whether a combination of two drugs, venetoclax and azacitidine, can effectively treat adults aged 18 to 59 who have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received any treatment. Participants take both drugs in cycles…

This early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This trial is testing an experimental oral drug called PXS-5505 (amsulostat) in people with myelofibrosis, a type of bone marrow cancer. The study focuses on patients who are not eligible for a stem cell transplant. The main goal is to see if the drug is safe and tolerable, and t…

This study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…

This study tracks adults with relapsed or refractory multiple myeloma who are already receiving isatuximab as part of their routine care. Researchers will measure how many patients respond to treatment, how long the response lasts, and how the drug affects quality of life and sid…

This phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This phase 3 trial tests whether a web-based physical activity program, including a wearable tracker and interactive app, can improve fitness and long-term health in children and adolescents who have completed cancer treatment. Participants are randomly assigned to receive either…

This Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …

This early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…

This early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…

This study tests whether adding the targeted drug venetoclax to standard chemotherapy helps more adults with acute myeloid leukemia (AML) achieve remission. It enrolls people aged 18 to 65 with intermediate- or high-risk AML who have not yet been treated. The main goal is to see …

This early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…

This early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …

This early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…

This phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…

This study tracks the safety and effectiveness of bosutinib (Bosulif) in people with chronic myelogenous leukemia (CML) who are either newly diagnosed or have not responded to or tolerated prior treatments. Researchers will monitor side effects and how well the drug controls the …

This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…

This study follows 36 Italian patients with Polycythemia Vera who responded well to Ropeginterferon alfa-2b in an earlier trial. Researchers will check every 6 months whether the treatment continues to keep their red blood cell levels normal and prevent the disease from getting w…

This phase 2 trial tests whether giving ruxolitinib (Jakafi) before, during, and after a stem cell transplant can improve outcomes for people with myelofibrosis. The study includes patients with intermediate-2 or high-risk disease, or intermediate-1 with additional risk factors. …

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…

This phase 2 trial is testing whether combining two drugs, ponatinib and 5-azacitidine, can improve survival in people with advanced chronic myeloid leukemia (CML). The study includes adults whose CML has progressed to an accelerated phase or a more aggressive blast crisis. Parti…

This study tests whether adjusting the daily dose of the leukemia drug dasatinib based on a patient's blood levels can improve safety and effectiveness. Adults newly diagnosed with chronic phase chronic myeloid leukemia (CML) will receive either standard dosing or a dose tailored…

This phase 2 trial tests whether adding pioglitazone (a diabetes drug) to the standard leukemia medication imatinib can eliminate remaining cancer cells in people with chronic-phase chronic myeloid leukemia (CML). Participants must have been on imatinib for at least two years and…

This trial tests whether adding the targeted drug ponatinib to standard chemotherapy (cytarabine) can help prevent relapse in adults with a specific, high-risk genetic form of acute myeloid leukemia (FLT3-ITD AML) who are already in first remission. The study includes two age gro…

This phase 2 trial tests whether the drug RAD001 (everolimus) can help control systemic mastocytosis, a rare condition where too many mast cells build up in organs like the bone marrow. Ten adults with the disease take a daily pill for 30 days. Researchers measure success by chan…

This trial investigates whether adjusting the dose of imatinib (Gleevec) based on the drug's level in the blood can improve outcomes for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). Participants whose imatinib blood level is low after 28 days are rand…

This study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is t…

This study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …

This pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…

This study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…

This trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard tra…

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This phase 3 trial is testing whether a combination of three drugs—azacitidine, venetoclax, and ATRA—can safely and effectively treat adults newly diagnosed with acute myeloid leukemia (AML). The drugs work together to stop cancer cell growth by demethylating DNA, promoting cell …

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…

This study tested a daily pill called E7820 in 12 adults with relapsed or treatment-resistant acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. All participants had specific mutations in splicing factor genes. The goal was to see if the drug c…

This study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often becomes resistant to standard treatments. Researchers took participants' own immune T cells, modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused …

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This study looked at the safety and effectiveness of a drug called asciminib in 85 Indian adults with a specific type of leukemia (Ph+ CML-CP). Some participants had a genetic mutation (T315I) that can make treatment harder, while others had already tried two or more other drugs.…

This study tested a new formulation of two chemotherapy drugs (CPX-351) in 56 adults with newly diagnosed acute myeloid leukemia (AML) who were at high risk of not responding to standard treatment. The goal was to find the best dose and see how well it worked to stop cancer cells…

This early-phase study tested whether specially grown immune cells (cytokine-induced killer cells) could safely treat blood cancers that return after a stem cell transplant. 21 adults with relapsed multiple myeloma or other blood cancers received these donor cells. The goal was t…

This phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …

This study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…

This early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…

This study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…

This phase 2 trial tested whether certain biomarkers in bone marrow can predict how well patients with high-risk acute myeloid leukemia (AML) respond to treatment with sirolimus plus standard chemotherapy (MEC). The study enrolled 39 adults with AML that was hard to treat or had …

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This phase 2 trial tests whether a combination of clofarabine and intermediate-dose cytarabine (CLARA) works better than high-dose cytarabine (HDAC) alone as consolidation therapy for younger adults (18-60) with newly diagnosed acute myeloid leukemia (AML). After initial remissio…

This study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…

This early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. …

This early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…

This study tested a new drug called S65487, which blocks a protein that helps leukemia cells survive, combined with the standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. Researcher…

This phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …

This phase 1 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 29 patients whose acute myeloid leukemia or myelodysplastic syndrome came back or did not respond after a donor stem cell transplant. The goal was to find the safest dose and see if the drugs could he…

This phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…

This early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…

This study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed tha…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control …

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…

This study looked at how safe and tolerable the drug Kyprolis is for Indian patients whose multiple myeloma has come back or stopped responding to treatment. A total of 101 adults took part, and researchers tracked side effects and how long the drug kept the cancer from getting w…

This study tested whether a special oral nutritional supplement (Ensure Complete) could help patients with blood cancer maintain weight and gut health after a stem cell transplant. One hundred participants were randomly assigned to receive either the supplement or a standard hosp…

This phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy…

This study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusio…

This study tested an experimental pill called Bomedemstat in 73 people with essential thrombocythemia, a rare blood condition causing too many platelets. Participants had already tried at least one standard treatment without success. The main goals were to check safety and see if…

This study tested whether an oral medication (CC-486) could help elderly patients with a serious blood disorder called myelodysplastic syndrome (MDS) maintain their improvement after initial injectable treatment. Eleven patients who had responded to injectable azacitidine switche…

This study tested different dosing schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to see if changing the dose or how often it is given could reduce serious eye…

This early-stage study tested a new drug called LYT-200 in 101 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had come back or stopped responding to treatment. The main goals were to check the drug's safety and find the right dose. While not…

This study tested a new way to deliver total body radiation to adults with blood cancers who need a stem cell transplant. The goal was to see if this method could effectively target cancer while protecting the lungs. 36 patients took part, and the study focused on safety and how …

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This study tested adding elotuzumab to a standard three-drug combination (bortezomib, lenalidomide, dexamethasone) for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and se…

This Phase 2 study tested avapritinib, a daily tablet that targets a specific genetic mutation, in 107 people with advanced systemic mastocytosis (a rare blood cancer). The main goal was to see how many patients had their tumors shrink or symptoms improve. Results suggest the dru…

This early-phase study tested a two-drug combination (pevonedistat plus decitabine) in 12 people with high-risk acute myeloid leukemia (AML), including those who had relapsed or couldn't tolerate standard chemo. The main goal was to find the safest dose and identify side effects.…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This phase 2 trial tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep remission (stringent co…

This phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete response…

This early-phase study tested whether giving specially selected donor immune cells (NK cells) soon after a stem cell transplant is safe for people with blood cancers. Seventeen patients received the cells, and researchers monitored for serious side effects within 30 days. The goa…

This early study tested the drug belimumab (Benlysta) to see if it could prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. GvHD is a serious condition where the donor's immune cells attack the patient's body. The main g…

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and…

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This study offers continued treatment with elotuzumab (plus dexamethasone) to 67 multiple myeloma patients who were already benefiting from it in earlier trials. The main goal is to keep providing the drug and track how long patients stay on treatment. Researchers will also monit…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if…

This study tested a new drug, crenolanib, against the standard drug midostaurin in adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). All 214 participants received standard chemotherapy and, if eligible, a bone marrow transplant, plus one of the two…

This phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could le…

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after initial chemotherapy. The goal was to find the right dose and see if it safely delays the cancer from coming back. The study…

This study tested a combination of two drugs, azacitidine and venetoclax, in 42 elderly patients (age 60+) with newly diagnosed acute myeloid leukemia (AML) who could not have standard chemotherapy. The treatment was given as an initial 'induction' phase, followed by a 'maintenan…

This study tested whether adding the drug crenolanib to standard chemotherapy helps adults up to age 75 with a hard-to-treat form of acute myeloid leukemia (AML) that has a specific genetic change (FLT3 mutation). Participants received either crenolanib or a placebo alongside che…

This phase II trial tested whether a newer antibiotic combination (imipenem-relebactam) works better than standard antibiotics for treating fever caused by low white blood cell counts in cancer patients. About 100 adults with cancer or who had a stem cell transplant took part. Th…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested a drug called CT-011 (a PD-1 blocker) and a dendritic cell vaccine given after a stem cell transplant in 35 people with multiple myeloma. The goal was to see if this combination is safe and can boost the immune system to fight remaining cancer cells. Researchers…

This study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…

This phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how we…

This phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see how many patients' tumors shrank or disappeared. The treatment is not a cure, but aims to control …

This study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…

This study tested a drug called GO-203-2C, which targets a protein (MUC1) found on cancer cells while sparing healthy cells. It was given alone or with another drug (decitabine) to 33 adults with acute myeloid leukemia that had returned or not responded to treatment. The main goa…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This study tested a new treatment called CTX131 for adults with certain blood cancers (T-cell lymphoma, B-cell lymphoma, or acute myeloid leukemia) that had returned or stopped responding to standard therapy. CTX131 uses a patient's own immune cells, modified with CRISPR gene edi…

This study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…

This study tested whether adding a drug called vorinostat to the standard combination of lenalidomide and dexamethasone could help patients whose multiple myeloma had stopped responding to lenalidomide. The trial enrolled 25 adults with relapsed or refractory multiple myeloma. Th…

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This study tested whether denosumab, a drug given as a shot every 6 months, can improve bone density in people with osteoporosis caused by systemic mastocytosis. 24 adults with the condition took part. The goal was to see if the drug strengthens bones and prevents fractures bette…

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This phase II trial tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) can better prevent graft-versus-host disease (GVHD) in 59 patients with blood cancers receiving donor stem cell transplants. GVHD occurs when donor immune cells attack…

This study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…

This study tested a new method of cord blood transplantation in 13 children and young adults with high-risk myeloid cancers. The approach uses a molecule called UM171 to grow more stem cells from a single cord blood unit, aiming to speed up recovery and reduce complications. Earl…

This study tested a new way to prepare patients with relapsed or hard-to-treat acute leukemia for a donor stem cell transplant. It combined a precise form of radiation therapy (IMRT) with two chemotherapy drugs (etoposide and cyclophosphamide) before the transplant. The goal was …

This study tested whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. The main goal was to see if the combination could shrink an enlarged spleen by at le…

This study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recove…

This study looked at whether children with cancer and a fever caused by low white blood cells can safely stop antibiotics earlier than usual. 55 children took part, and half stopped antibiotics once their fever was gone for 48 hours, while the other half continued until their whi…

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tested a new way to treat high-risk multiple myeloma using umbilical cord blood that was expanded in the lab with a molecule called UM171. Nineteen patients received this special transplant to see if it was safe and could help control the disease. The goal is to improv…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …

This early-phase study tested a combination of two drugs, venetoclax and omacetaxine, in 6 adults with acute myeloid leukemia (AML) whose cancer had stopped responding to venetoclax-based treatments. The main goal was to find the safest dose of omacetaxine when given with venetoc…

This early-phase trial tested a new type of stem cell transplant called a microtransplant in 25 people with myeloid blood cancers (like leukemia) who were too old or frail for a standard transplant. Unlike a regular transplant, this one used stem cells from a partially matched fa…

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…

This phase 2 pilot study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 55 people with high-risk smoldering multiple myeloma, a condition that often leads to active myeloma. The goal was to see if the treatment could eliminate signs of the dis…

This early-phase trial tested a combination of two drugs, ibrutinib and lenalidomide, in 4 patients with myelodysplastic syndrome (MDS) who had not responded to or could not tolerate standard treatments. The main goal was to find the safest dose and identify side effects. While t…

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …

This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…

This study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and cont…

This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This study tested a new way to treat multiple myeloma by starting with just two drugs (bortezomib and dexamethasone) and adding a third (lenalidomide) only if the disease wasn't well controlled. The goal was to see if this step-by-step approach could achieve the same good results…

This early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…

This early-phase trial tested a cancer vaccine (CDX-1401) along with an immune booster, chemotherapy, and an immunotherapy drug in 8 people with myelodysplastic syndrome (MDS) or low-blast acute myeloid leukemia (AML). The goal was to see if the combination is safe and helps the …

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This Phase 3 trial tested a special cord blood product called NiCord (omidubicel) against standard cord blood transplants in 125 people with blood cancers like leukemia and lymphoma. The goal was to see if NiCord helps the body rebuild its infection-fighting cells faster. Researc…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This study tested whether a shot under the skin (subcutaneous) works as well as an IV drip for the drug isatuximab in people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. All participants also received standard chemotherapy. The goal was to se…

This early-phase trial tested a new CAR-T cell therapy called C-CAR088 in 9 patients with multiple myeloma that had returned or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cells. The main goal…

This study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to prior treatments. 302 adults who had already received 1 to 3 prior therapies took part…

This study tested a new way of giving the drug elranatamab to people with multiple myeloma that came back or didn't respond to treatment. The drug was given as a shot under the skin, starting with low doses and then increasing, with longer breaks between doses over time. The goal…

This study looked at how adults with a specific type of acute myeloid leukemia (AML) who cannot receive standard chemotherapy feel and function while taking a combination of ivosidenib and azacitidine. The main goal was to measure quality of life using questionnaires, along with …

This study tested a combination of pomalidomide and dexamethasone in 63 patients with multiple myeloma that had returned or stopped responding to treatment, and who had specific high-risk genetic changes. The goal was to see how well the drugs controlled the disease and what side…

This study tested a three-drug chemotherapy combination (cladribine, homoharringtonine, and cytarabine) in 65 adults under 60 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how well it wiped out leukemia cells and how safe it was. Results tracked complete …

This early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This study tested a drug called navitoclax, either alone or added to the standard drug ruxolitinib, in 191 people with myelofibrosis. The main goal was to see if the treatment could shrink the spleen by at least 35% after 24 weeks. The trial also looked at whether it could reduce…

This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This study tested different drug combinations in 1,503 adults aged 18-65 with newly diagnosed multiple myeloma. The goal was to see which approach—standard drugs or high-dose chemo with stem cell transplant—works better to delay the cancer's return. Patients received maintenance …

This early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…

This study tested whether the antibiotic levofloxacin can prevent fevers and infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving the chemotherapy drug azacitidine. Infections are a major risk for these patients. The trial ran…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This study tested whether brushing teeth is safe for patients with prolonged aplasia (low blood cell counts) after intensive chemotherapy. Currently, many hospitals only allow mouthwash to avoid bleeding and infection. The trial compared brushing with an extra-soft toothbrush plu…

This phase 3 study tested whether adding daratumumab to standard pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma live longer without their disease getting worse. 304 adults who had already tried lenalidomide and a proteasome inhibitor took…

This study tested whether a stem cell transplant from a matched donor could improve outcomes for myeloma patients under 65 who had already responded well to their own stem cell transplant. Thirteen patients received a reduced-intensity conditioning regimen followed by the donor t…

This phase 2 trial tested a three-drug combination (ixazomib, cyclophosphamide, and dexamethasone) in 112 patients with multiple myeloma that had returned or stopped responding to three previous treatments. The goal was to see if adding ixazomib to standard chemotherapy could hel…

This study looked at how well the drug Venetoclax works for adults with acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 120 patients in Switzerland and Austria took Venetoclax pills daily as part of their normal care. Researchers tracked …

This early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…

This study tested a combination of three drugs—pomalidomide, cyclophosphamide, and dexamethasone—in 100 patients with multiple myeloma that had returned after initial treatment. All patients had previously been part of the IFM/DFCI 2009 trial. The goal was to see how many patient…

This study tested an oral liquid form of arsenic trioxide (SDK001) in 12 people with acute promyelocytic leukemia (APL). Researchers compared how well the body absorbs the oral drug versus the standard IV version, and whether food or calcium supplements change absorption. The goa…

This study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…

This early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…

This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…

This completed Phase 1 trial tested a new drug called IkT-001Pro in 64 healthy adults aged 18 to 55. The goal was to see if it works like the standard CML drug imatinib in the body. Participants took single doses of both drugs at different times to compare how they are absorbed a…

This early-phase trial tested a combination of three drugs—selinexor, carfilzomib, and dexamethasone—in 52 patients with multiple myeloma that had returned or stopped responding to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope t…

This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…

This study tested whether tranexamic acid, a drug that helps blood clot, can lower the risk of serious bleeding or death in people with blood cancers who have dangerously low platelet counts. Over 600 adults receiving chemotherapy or a stem cell transplant were randomly given eit…

This study tested whether adding pevonedistat to the standard drug azacitidine helps people with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia live longer without their disease getting worse. About 454 adults took part…

This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…

This study tested whether adding a drug called pevonedistat to the standard two-drug combination (venetoclax and azacitidine) helps adults recently diagnosed with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. About 164 participants received either the…

This study tested a new drug called asciminib in 56 adults with chronic myeloid leukemia (CML) whose cancer had not responded well to other treatments. The drug is taken as a pill and aims to control the disease. The main goal was to check safety and side effects over 24 weeks, w…

This early-stage study tested a new drug called JNJ-74856665 in 153 people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). The main goals were to find safe doses and check for side effects when given alone or with oth…

This study tested whether adding a second drug (pegylated interferon) to the standard leukemia medication nilotinib helps people with newly diagnosed chronic myeloid leukemia (CML) achieve a deeper molecular response faster. About 200 adults under 65 with early-stage CML took par…

This study tested whether fasting for at least 14 hours each night could help overweight people with early blood cancer conditions (MGUS, smoldering myeloma) lose weight and possibly lower their cancer risk. Twenty-three participants were randomly assigned to either the fasting p…

This study tested whether a procedure called extracorporeal photophoresis (ECP) could prevent graft-versus-host disease (GVHD) in 158 people receiving stem cell transplants for blood cancers. ECP involves removing white blood cells, treating them with a light-sensitive drug and U…

This study looks at the long-term safety of bomedemstat, an oral drug, in 81 people with myeloproliferative neoplasms (MPNs) like essential thrombocythemia and primary myelofibrosis. Participants had already taken bomedemstat in a prior study. Researchers tracked side effects, sp…

This phase 2 trial tested a powerful combination of chemotherapy drugs followed by stem cell transplants in 40 patients under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The goal was to see if this intensive approach could improve how long patients l…

This study tested a two-step (tandem) stem cell transplant in 148 people with multiple myeloma. Patients received high-dose melphalan chemotherapy, followed by a second transplant with melphalan plus bortezomib (Velcade). The goal was to see if this approach could delay cancer pr…

This phase 2 study tested a combination of three drugs—carfilzomib, pomalidomide, and dexamethasone—in 54 adults whose multiple myeloma had come back after one or two prior treatments. The goal was to see how many patients responded to the therapy. The study is complete, and resu…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

This early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five day…

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…

This study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…

This completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…

This trial tests whether a single high dose of vitamin A, given before a donor stem cell transplant, can prevent gastrointestinal graft-versus-host disease (GVHD), a condition where donor cells attack the gut. Vitamin A deficiency is linked to a higher risk of this complication, …

This study tests whether moxibustion, a traditional therapy that burns herbs near the skin, can prevent hemorrhagic cystitis (painful bladder inflammation) in 266 patients receiving stem cell transplants. Participants are randomly assigned to receive either standard care or stand…

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received…

This study tested whether sitagliptin, a diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. Participants took sitagliptin along with standard GVHD prevention. The main goal was to…

This phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment cou…

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This trial tests whether an AI emotional companion app can improve depression, anxiety, and demoralization in adults with advanced cancer. Participants use a mobile app where a virtual character holds conversations, reads emotional cues, and offers a link to a human hotline if di…

This trial tests whether laser acupuncture, a non-invasive therapy using low-intensity light on traditional acupoints, can relieve constipation in people with advanced cancer. Participants are adults with advanced cancer who have constipation despite using laxatives. The study me…

This trial tests whether personalized education from a nurse can help people newly diagnosed with multiple myeloma better handle side effects from the drug bortezomib. Participants receive either standard care or two one-on-one teaching sessions covering symptoms like nerve pain,…

This study looked at how satisfied people were with three different types of mouthguards (occlusal splints) for jaw joint and muscle pain (TMD). 27 adults who had jaw pain for at least 3 months and had never been treated for it tried one of the splints. The main goal was to see w…

This phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…

This trial tests whether a phone-based positive psychology program can improve mood, quality of life, and daily functioning in adults who have just undergone a stem cell transplant for blood cancer. Participants receive weekly calls and complete exercises focused on gratitude, pe…

This trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This early-stage study looked at whether giving two standard chemotherapy drugs (cytarabine and daunorubicin) in a different way could be safer for the heart in adults newly diagnosed with acute myeloid leukemia (AML). Researchers used heart MRI scans to monitor for damage. The g…

This study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…

This study tests whether a hospital-at-home care model can help people with advanced blood cancers receive end-of-life care at home instead of in the hospital. Participants use remote monitoring and home-based supportive care, with researchers tracking how many enroll and complet…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study tested whether a mobile health program—including a Fitbit with movement reminders, coaching sessions, and a WhatsApp peer support group—could help 20 adolescents and young adults with acute lymphoblastic leukemia (ALL) reduce the time they spend sitting or lying down d…

This study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …

This study tested a support program for people caring for a loved one undergoing a stem cell transplant for blood cancer. The program included 8 online sessions over 12 weeks to teach stress management, coping skills, and communication. 17 caregivers took part, and the study chec…

This study explored whether multiple myeloma patients could safely administer the drug Carfilzomib at home instead of always going to the hospital. Nine patients who had already received at least one treatment cycle in the clinic were taught to give themselves the infusion on cer…

This study looked at whether a type of talk therapy called cognitive-behavioral therapy (CBT) can help reduce the severe tiredness that many people feel after a stem cell transplant for blood cancer. 66 adults who had a transplant at least 6 months earlier and still had significa…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…

This study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…

This study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…

This study tested a structured educational program called the Myeloma Pack for people with multiple myeloma. The goal was to see if it could reduce anxiety and depression and improve quality of life. 85 patients took part while receiving standard cancer treatment. Researchers mea…

This study tested a set of dermo-cosmetic products (hand/foot serum, nail strengthener, dissolving oil, and gloves/slippers) in 20 multiple myeloma patients receiving bispecific antibody therapy. The goal was to see if these natural-based products could prevent or reduce skin and…

This pilot study tested whether a mobile exercise app (GO-EXCAP) is feasible for older patients (60+) with myeloid neoplasms who are receiving chemotherapy. 25 participants used the app for 7 weeks. The goal was to see if patients would actually use the app and stick with the pro…

This study tested an online educational program for cancer patients receiving chemotherapy. The program included video sessions, peer discussions, and digital materials to help with symptom management and emotional coping. Researchers compared 212 patients who used the program to…

This study tested whether mindfulness meditation training could help patients who are undergoing a stem cell transplant and staying in a sterile room. 70 adult patients participated, and the researchers measured their anxiety and sleep quality before and after the meditation prac…

This study tested whether a supervised 8-week exercise program (strength, endurance, and flexibility) could help patients recover after an autologous stem cell transplant. Fifteen adults with blood cancers were randomly assigned to exercise or usual care. The researchers measured…

This study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…

This study looked at whether starting supportive care (like meetings with a nurse, psychologist, or dietitian) right after a multiple myeloma diagnosis helps patients feel better compared to waiting 6 months. Twenty patients took part, and researchers measured their quality of li…

This study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-poi…

This study tested two treatments—laser therapy and ozone gas—to relieve painful mouth sores caused by cancer treatment. Forty adults with head and neck or blood cancers took part. Each received one treatment daily for five days. The goal was to see which therapy better reduced so…

This study looked at whether adding heart rate biofeedback training to regular physical activity can improve quality of life for people who have finished treatment for blood cancers. 80 adults in remission took part. The goal was to see if this combination helps them feel better …

This study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…

This study looked at whether 12 weeks of high-intensity interval training (HIIT) and resistance training could help people who had a stem cell transplant for blood cancer. It involved 16 patients and their caregivers. The goal was to see if exercise improves physical function, th…

This study tested whether using augmented virtual reality (AVR) during chemotherapy can help reduce pain, stress, and anxiety while boosting self-confidence. 150 adult cancer patients in the West Bank were split into two groups: one received standard care, and the other used AVR …

This study looked at whether early, regular visits from a palliative care team can improve quality of life for adults with acute leukemia that has returned. 49 patients were assigned to either receive this extra support or standard care. The team addressed physical, emotional, an…

This study looks back at the medical records of about 266 adults who received CAR T-cell therapy for blood cancers. The goal is to describe lung complications that happen within 30 days or up to 2 years after treatment. Researchers will also look for patient characteristics that …

Researchers are using wearable sensors and smartphone check-ins to track fatigue as it happens in people with myeloma, long COVID, heart failure, and healthy controls. Participants wear an ECG patch and a wrist sensor that measure heart rate, activity, and posture, and they rate …

This study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…

This study looks at how the adrenal glands work in people who are critically ill, such as those with sepsis. Adrenal insufficiency may affect up to 77% of ICU patients, but current tests are not reliable. Researchers will measure hormone levels in 225 participants, including heal…

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …

This study looks at whether a short risk-assessment tool, called the CARG score, can predict severe side effects from chemotherapy in cancer patients aged 70 and older. Participants will answer questions about their health and daily function before starting a new chemotherapy reg…

This trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…

This study looks at how a simple monitor called the Pleth Variability Index (PVI) changes during laparoscopic-assisted vaginal hysterectomy. Researchers will track PVI at six key moments when the patient's body position changes, such as tilting the head down or raising the legs. …

This study looks back at medical records of people who had an allogeneic stem cell transplant to see whether romiplostim helped their platelets recover faster. Platelets are blood cells that help clotting, and low counts are common after transplant. The researchers will compare p…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

Multiple myeloma, a common blood cancer, often causes bone lesions that lead to pain, fractures, and other serious events. This study reviews medical records of patients diagnosed between 2019 and 2021 to describe how often these bone complications occur and what rehabilitation s…

This study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…

This study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…

This study tests two devices — a wearable temperature patch and a smartphone app that measures vital signs from a facial scan — in adults with blood cancers receiving CAR-T or bispecific T-cell engager therapy. The goal is to see if these tools can detect fevers and other signs o…

This study is not testing a new treatment. Instead, researchers in Italy are observing how doctors currently treat a tough form of multiple myeloma that no longer responds to three main drug classes. They will collect information from medical records of about 250 patients across …

This study looks back at medical records of over 300 adults with relapsed/refractory multiple myeloma to compare how well different drug combinations work in everyday practice. Researchers are analyzing outcomes like how long patients live without their cancer worsening and overa…

This study looks back at medical records from a single hospital in Scotland to see how well the drug bosutinib works and how safe it is for people with chronic myeloid leukemia (CML) in everyday practice. Researchers will track blood cell counts, genetic responses, and side effec…

This early-phase trial tested whether adding atovaquone (a drug usually used to prevent pneumonia) to standard chemotherapy is safe and reaches effective levels in the blood. It involved 26 children and young adults (ages 1 month to 21 years) newly diagnosed with acute myeloid le…

This study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…

This study aims to develop a standardized reference guide for pharmacists to use during initial consultations with multiple myeloma patients starting oral chemotherapy. The goal is to provide clear, consistent information that helps patients understand and follow their treatment …

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…

This completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.

This completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…

This study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…

This study looked back at medical records of 100 adults with multiple myeloma that had returned after initial treatment. Researchers compared how long patients stayed cancer-free on four different three-drug combinations. The goal was to see which combination worked best in real-…

This completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…

This completed study looked at blood vessel cells from 30 people with primary myelofibrosis, a rare bone marrow disorder. Researchers wanted to see if these cells act like stem cells that could be the origin of the disease. By growing the cells in the lab, they aimed to understan…

This study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…

This pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…

This study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML), their caregivers, and their doctors communicate better and make decisions together. It involved 161 participants aged 60 and older. The goal was to see if the tool improved shared de…

This study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what factors are most important to them when deciding on a treatment. No new drugs or therapies were tested; instead, the stud…

This study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising …

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict ho…

This pilot study tested a communication tool called UR-GOAL in 15 older adults (age 60+) with newly diagnosed acute myeloid leukemia (AML), along with their caregivers and doctors. The tool helps patients share their preferences and goals, so treatment decisions better match what…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This study tests whether measuring two substances in the blood—FLT3L and IL-6—during chemotherapy can help predict survival in people with acute myeloid leukemia (AML). Researchers will track 201 newly diagnosed AML patients across 25 French hospitals. The goal is to confirm that…

This study looked at 182 older adults with blood cancer or lung cancer to see if a special calculator could predict who would have severe side effects from chemotherapy. Researchers measured patients' fitness before and after treatment to better understand how well they could han…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study tested a program to help older patients (age 60+) with blood cancers plan their future medical care while in the hospital. The program focused on completing advance directives and healthcare proxy forms. Out of 41 participants, the study found that the program was feas…

This study tested whether a telehealth program could help older patients (60+) with acute myeloid leukemia or myelodysplastic syndrome discuss and document their future medical wishes. Researchers enrolled 36 patients, caregivers, and clinicians to see if the program was easy to …

This study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…

This study looked at how well two different capsule forms of TP-3654 are absorbed by the body and whether taking them with food changes absorption. It involved 24 healthy adults and was completed. The results will help design future studies for people with myelofibrosis, a bone m…

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …

This study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…

This study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…

This study looked back at 60 adult blood cancer patients who had stem cell transplants and later developed a rare fungal infection called mucormycosis. Researchers compared cases before COVID-19 (2015-2020) to during the pandemic (2020-2024) to see if the virus, new tests, or new…

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study looked at the safety of the drug Ninlaro (ixazomib) when used to treat multiple myeloma in everyday medical practice in China. About 482 patients were observed, and researchers recorded any side effects or dose changes. The goal was to gather real-world safety informat…

This study looked at 70 patients who had a stem cell transplant for blood cancer. Researchers measured levels of complement proteins in the blood to see if they are linked to graft-versus-host disease, a common and serious side effect. The goal is to better understand how inflamm…

This study tested a program called FinFit to help adolescent and young adult cancer survivors deal with money problems caused by their illness. Researchers interviewed 16 people from community cancer clinics to design and improve the program. The goal was to figure out the best w…

This study measured certain proteins in the blood and urine of 20 newly diagnosed multiple myeloma patients before and 30 days after starting daratumumab. The goal was to see if these markers could help detect early kidney injury. Participants provided samples during routine lab …

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…

This study looked at 232 adult cancer patients with sepsis and low blood pressure to see if adding a type of antibiotic called aminoglycosides helps them recover faster. The main goal was to see how quickly their blood pressure returned to normal without needing strong blood pres…

This completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood a…

This completed study collected real-world data from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. The goal was to describe patient characteristics, treatment patterns, and outcomes like relapse and…

This completed study enrolled over 2,100 people with or suspected of having myelodysplastic syndromes (MDS), a group of blood disorders. Researchers collected medical data, blood, and tissue samples over time to track how the disease develops and progresses. The goal was to creat…

This completed study looked at how common gut inflammation and leaky gut are in 80 adults with blood cancer who were in intensive care for sepsis or septic shock. Researchers measured two markers—calprotectin in stool and zonulin in blood—to better understand intestinal dysfuncti…

This study explored whether a simple blood test (liquid biopsy) and a whole-body MRI can detect leftover cancer cells in people with multiple myeloma, potentially replacing the need for a bone marrow biopsy. Researchers enrolled 36 adults with newly diagnosed or previously treate…

This study looked at 1,753 patients needing a stem cell transplant for blood cancers or other serious blood disorders. Researchers compared two strategies: first searching for a matched unrelated donor, then trying an alternative donor if needed, versus going straight to an alter…

This study tested whether a small, swallowable capsule can accurately measure body temperature in 30 hospitalized patients with blood cancers who have very low immunity (neutropenia). Researchers compared the capsule's temperature readings to standard ear thermometer measurements…

This pilot study looked at ovarian tissue from 9 young women with acute myeloid leukemia who had it frozen to preserve fertility before a stem cell transplant. Researchers checked the frozen tissue for any leftover leukemia cells. The goal was to see if the tissue might be safe t…

This study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…

This pilot study looked at 20 adults with acute myeloid leukemia (AML) who were not healthy enough for strong chemotherapy. They received a standard combination of azacitidine and venetoclax. Researchers measured venetoclax levels in the blood at several time points to see if tho…

This study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…

This study looked at how faithfully adults with multiple myeloma (a type of blood cancer) follow their prescribed carfilzomib combination treatments in everyday medical practice. It included 359 patients who had already tried at least one prior therapy. The goal was to measure ad…

This study looked at 57 people who had a stem cell transplant for blood cancer. Researchers wanted to see if certain immune cells (iNKT cells) could help predict the risk of graft-versus-host disease (GVHD), a serious side effect. They measured these cells in the blood and the tr…

This study looked at whether a special type of scan (PET/CT) can help doctors see if treatment for a serious fungal lung infection is working earlier than usual. It involved 51 adults with blood cancer and invasive pulmonary aspergillosis. The goal was to see if the scan results …

This study observed 113 adults in Italy with acute myeloid leukemia (AML) linked to prior cancer therapy or bone marrow problems. All participants received Vyxeos liposomal as part of their normal care. Researchers tracked how many achieved complete remission without detectable d…

This study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy contro…

This study tested whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Ten doctors reviewed bone marrow samples with and without AI assistance. The goal was to see if AI improves …

This study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…

This study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …

This study looked back at the medical records of 400 adults with a specific type of acute myeloid leukemia called core binding factor (CBF) leukemia. Researchers wanted to see how well current treatments work and what factors affect outcomes, such as genetic mutations and signs o…

This study followed 267 adults who had stem cell transplants to understand why some develop chronic graft-versus-host disease (GVHD), a common complication. Researchers collected blood, saliva, tears, and tissue samples, along with eye scans and breathing tests, to find early sig…

This completed study looked at 552 adults with myeloproliferative neoplasms (MPN) who also had COVID-19. Researchers wanted to see how often these patients developed blood clots, like pulmonary embolism. The goal was to understand what factors make COVID-19 worse for people with …

This completed study measured normal tryptase levels in 402 children aged 0-18 to help doctors better diagnose mast cell disorders like mastocytosis and MCAS. Researchers used leftover blood from routine tests in children undergoing surgery. Knowing these normal ranges could redu…

This completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…

This study looked at whether a special type of PET scan can help doctors diagnose and treat a rare fungal infection of the liver and spleen in people with blood cancer or those who had a stem cell transplant. The infection often appears after severe neutropenia (low white blood c…

This study enrolled 349 people with myelodysplastic syndromes (MDS) to see how certain gene mutations affect survival. Researchers collected blood samples at diagnosis and tracked patients over time. The goal was to understand which mutations are linked to better or worse outcome…

This study collected blood samples from nearly 1,900 people in families where at least two members have a type of dysglobulinemia, including multiple myeloma, MGUS, or Waldenström's disease. Researchers will analyze the DNA to look for genetic variations that might increase the r…

The aim is to investigate the feasibility, safety, and complication rates of patient's self-measurement of CBC and self-administration of blood and platelet transfusions at home and examine the performance of patients conducting at-home monitoring of their blood pressure, pulse r…

Combining the results of previous studies and based on the clinical practice in our center, we designed the Venetoclax in combination with 3days-Decitabine regimen for induction therapy in elderly or unfit AML patients with a primary diagnosis, and set Venetoclax in combination w…

To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.